共 224 条
[1]
Aggarwal R(2022)Efficacy of high-dose intravenous immunoglobulin in severe and critical COVID-19: a retrospective cohort study Int Immunopharmacol 106 354-404
[2]
Dewan A(2021)Clinical outcomes of intravenous immunoglobulin therapy in COVID-19 related acute respiratory distress syndrome: a retrospective cohort study BMC Pulm Med 21 399-21902
[3]
Pandey A(2021)Hyperimmune anti-COVID-19 IVIG (C-IVIG) treatment in severe and critical COVID-19 patients: a phase I/II randomized control trial EClinicalMedicine 12 21866-8+72
[4]
Trehan N(2021)High-dose intravenous immunoglobulin in severe coronavirus disease 2019: a multicenter retrospective study in China Front Immunol 12 65-548
[5]
Majid MA(2021)Intravenous immunoglobulin therapy for critically Ill COVID-19 patients with different inflammatory phenotypes: a multicenter Retrosp Study Front Immunol 33 543-143
[6]
Ali HS(2021)Evaluation of clinical value of Xuebijing combined with human immunoglobulin in severe and critically ill patients with coronavirus disease 2019 Zhonghua Wei Zhong Bing Ji Jiu Yi Xue 13 139-400
[7]
Elshafei MS(2021)Efficacy and safety of current medications for treating severe and non-severe COVID-19 patients: an updated network meta-analysis of randomized placebo-controlled trials Aging (albany NY) 101 388-8
[8]
Saad MO(2022)Comparative efficacy and safety of pharmacological interventions for severe COVID-19 patients: an updated network meta-analysis of 48 randomized controlled trials Medicine (baltimore) 17 1036.e1-540
[9]
Mitwally HA(2022)Application value of xuebijing combined with gamma globulin in corona virus disease 2019 China J Pharm Econ 37 786-506
[10]
Al Wraidat M(2021)Effects of adjunct treatment with intravenous immunoglobulins on the course of severe COVID-19: results from a retrospective cohort study Curr Med Res Opin 24 530-531